Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CRSP

CRISPR Therapeutics AG

May 09 • 04:00PM ET

53.55

Dollar change +0.26
Percentage change 0.49	%

Healthcare • Biotechnology • Switzerland • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ARKK ARKG VXF IBB SCHA VHT XT SCHM LABU ITOT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.72	Insider Own	4.30%	Shs Outstand	84.88M	Perf Week	-2.76%
Market Cap	4.55B	Forward P/E	-	EPS next Y	-4.51	Insider Trans	-4.19%	Shs Float	81.24M	Perf Month	-13.27%
Income	-217.14M	PEG	-	EPS next Q	-1.52	Inst Own	65.66%	Short Float	18.15%	Perf Quarter	-22.20%
Sales	271.71M	P/S	16.73	EPS this Y	-193.94%	Inst Trans	-0.04%	Short Ratio	8.63	Perf Half Y	-8.59%
Book/sh	24.56	P/B	2.18	EPS next Y	20.97%	ROA	-9.27%	Short Interest	14.74M	Perf Year	-4.31%
Cash/sh	24.84	P/C	2.16	EPS next 5Y	-	ROE	-11.03%	52W Range	37.55 - 91.10	Perf YTD	-14.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.83%	ROI	-9.43%	52W High	-41.22%	Beta	1.79
Dividend TTM	-	Quick Ratio	17.81	Sales past 5Y	33402.13%	Gross Margin	51.71%	52W Low	42.61%	ATR (14)	2.57
Dividend Ex-Date	-	Current Ratio	17.81	EPS Y/Y TTM	59.83%	Oper. Margin	-101.29%	RSI (14)	35.35	Volatility	4.00% 4.08%
Employees	407	Debt/Eq	0.11	Sales Y/Y TTM	171.01%	Profit Margin	-79.91%	Recom	2.19	Target Price	84.64
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	-111.33%	Payout	-	Rel Volume	0.99	Prev Close	53.29
Sales Surprise	-97.81%	EPS Surprise	-5.08%	Sales Q/Q	-99.50%	Earnings	May 08 AMC	Avg Volume	1.71M	Price	53.55
SMA20	-4.45%	SMA50	-19.11%	SMA200	-9.91%	Trades		Volume	1,700,543	Change	0.49%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-11-23	Downgrade	TD Cowen	Market Perform → Underperform	$30
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-27-23	Initiated	Mizuho	Buy	$82
Aug-17-23	Upgrade	Citigroup	Neutral → Buy
May-30-23	Initiated	William Blair	Outperform	$75
Apr-13-23	Initiated	Cantor Fitzgerald	Overweight	$72
Mar-21-23	Initiated	Bernstein	Mkt Perform	$44
Mar-17-23	Initiated	Bryan Garnier	Buy	$70
Mar-07-23	Initiated	Robert W. Baird	Neutral	$46
Oct-11-22	Initiated	Morgan Stanley	Underweight	$37
Aug-09-22	Downgrade	Barclays	Overweight → Equal Weight	$99 → $88
Jun-23-22	Downgrade	Evercore ISI	Outperform → In-line	$66 → $60
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$98
Apr-28-22	Initiated	Credit Suisse	Neutral	$78
Dec-07-21	Initiated	Cowen	Market Perform
Oct-19-21	Initiated	SVB Leerink	Outperform	$126
Jun-14-21	Upgrade	Citigroup	Sell → Neutral	$55 → $132
Apr-21-21	Upgrade	Jefferies	Hold → Buy	$172
Mar-04-21	Initiated	JMP Securities	Mkt Outperform	$160

Show Previous Ratings

May-09-24 11:12AM	Barclays Adjusts Price Target on CRISPR Therapeutics to $67 From $80, Maintains Equal-Weight Rating (MT Newswires)
11:11AM	Needham Adjusts Price Target on CRISPR Therapeutics to $88 From $90, Keeps Buy Rating (MT Newswires)
10:58AM	CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss (Zacks)
10:12AM	Baird Adjusts Price Target on CRISPR Therapeutics to $52 From $46, Keeps Neutral Rating (MT Newswires)
08:30AM	CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference (GlobeNewswire)
06:49AM	Loading…
06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
May-08-24 10:58PM	CRSP Stock Earnings: CRISPR Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:40PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
05:10PM	CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:00PM	CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
07:00AM	CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach (GlobeNewswire)
May-06-24 12:43PM	CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards? (Zacks)
May-04-24 12:00PM	3 Biotech Stocks With the Potential to Make You an Overnight Millionaire (InvestorPlace)
May-03-24 05:50PM	CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know (Zacks)
02:18PM	Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's Radar (InvestorPlace)
08:45AM	Loading…
08:45AM	3 Growth Stocks You'll Kick Yourself for Not Buying Today (InvestorPlace)
May-02-24 07:15AM	3 Biotech Stocks to Buy and Hold Through 2030 and Beyond (Motley Fool)
06:04AM	3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace)
May-01-24 11:59AM	Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge (InvestorPlace)
09:00AM	Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock (Zacks)
Apr-26-24 05:50PM	CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note (Zacks)
Apr-25-24 07:00AM	Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth (Reuters)
Apr-22-24 06:00PM	CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why (Zacks)
04:30PM	CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting (GlobeNewswire)
12:49PM	Cathie Wood's Latest Stock Portfolio: Top 10 Stock Picks (Insider Monkey)
Apr-19-24 10:31PM	CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact (TipRanks)
06:56AM	ChatGPT Stock Predictions: 10 Stocks That Have 10X Potential (Insider Monkey)
Apr-17-24 09:00AM	Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now? (Zacks)
Apr-16-24 06:00PM	CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know (Zacks)
Apr-13-24 08:47AM	3 Magnificent Stocks That Could Double or More by 2030 (Motley Fool)
01:10PM	Loading…
Apr-11-24 01:10PM	Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024 (InvestorPlace)
Apr-10-24 01:46PM	Innovation in Healthcare: HTECs Q1 2024 Index Rebalance (ETF Trends) -5.29%
Apr-09-24 06:00PM	CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider (Zacks)
10:00AM	Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics (Motley Fool)
Apr-05-24 05:03AM	Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics (Motley Fool)
Apr-04-24 06:15PM	CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know (Zacks)
Apr-03-24 08:00AM	CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 08:00AM	CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting (GlobeNewswire)
Mar-30-24 06:50AM	3 Unstoppable Stocks to Buy Hand Over Fist in April (Motley Fool)
Mar-28-24 08:39AM	3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition (InvestorPlace)
Mar-27-24 04:50AM	3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000 (Motley Fool)
Mar-25-24 06:15PM	CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
Mar-24-24 10:08AM	Cathie Wood's Stock Portfolio: 2024 Stock Picks (Insider Monkey)
Mar-23-24 06:45AM	Buying These Dirt-Cheap Stocks Could Be a Brilliant Move (Motley Fool)
Mar-22-24 11:30AM	CRISPR Therapeutics (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-21-24 04:19PM	3 Stocks That Could Be the Next Big Thing in Gene Editing (InvestorPlace)
Mar-20-24 01:49PM	3 Biopharma Stocks Predicted to Soar in Q2 2024 (InvestorPlace)
Mar-19-24 06:15PM	CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know (Zacks)
12:07AM	Insider Sell: CFO Raju Prasad Sells Shares of CRISPR Therapeutics AG (CRSP) (GuruFocus.com)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-16-24 08:45AM	Is It Too Late to Buy CRISPR Therapeutics Stock? (Motley Fool)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 02:25PM	7 Biotech Stocks to Buy as Sector Rotation Ramps Up (InvestorPlace)
08:30AM	CRISPR Therapeutics Proposes New Appointment to the Board of Directors (GlobeNewswire)
Mar-06-24 02:45PM	The Top 3 Biotech Stocks to Buy in March 2024 (InvestorPlace)
Mar-05-24 06:53PM	Here's Why CRISPR Therapeutics Stock Climbed 34% in February (Motley Fool)
Mar-04-24 11:02AM	ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential (InvestorPlace)
08:48AM	12 Tech Stocks To Sell Right Now According To Cathie Wood (Insider Monkey)
Feb-29-24 05:32PM	Crispr Therapeutics CEO: Science in gene editing is moving at break-neck speed (CNBC TV)
06:31AM	CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst (Motley Fool)
05:50AM	A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now (Motley Fool)
Feb-27-24 12:00PM	3 Biotech Stocks Bound to Blast Off By 2029 (InvestorPlace)
Feb-26-24 08:50AM	3 Biotech Stocks to Buy and Hold for the Next 10 Years (Motley Fool)
06:45AM	Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold (Motley Fool)
Feb-23-24 10:01AM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
Feb-22-24 07:37AM	CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up (Zacks)
04:00AM	13 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Feb-21-24 04:32PM	Crispr Stock Whipsaws As Wall Street Watches Its Gene-Editing Blockbuster Candidate (Investor's Business Daily)
10:15AM	Crispr Reports Its First Profit In 10 Quarters, But Shares Trade Sideways (Investor's Business Daily)
07:30AM	CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-20-24 05:02AM	Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought (Motley Fool)
Feb-19-24 04:08PM	3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential (InvestorPlace)
01:45AM	If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today (Motley Fool)
Feb-16-24 02:19PM	3 Stocks That Cathie Wood Is Loving Now: February 2024 (InvestorPlace)
07:31AM	CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last? (Zacks)
Feb-15-24 08:30AM	CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit (GlobeNewswire) +6.88%
Feb-14-24 08:15AM	CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards? (Zacks) +8.60%
Feb-13-24 01:22PM	CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ (Investor's Business Daily)
10:00AM	CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
08:30AM	CRISPR Therapeutics Announces $280 Million Registered Direct Offering (GlobeNewswire)
02:30AM	European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) (GlobeNewswire)
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-09-24 06:00PM	CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why (Zacks)
Feb-08-24 02:59AM	2 Healthcare Stocks to Buy Hand Over Fist in February (Motley Fool)
Feb-07-24 10:00AM	Cathie Wood Just Bought These 3 Biotech Stocks. Should You? (Motley Fool)
09:09AM	Jim Cramer Says You Should Stay Away from These 10 Stocks (Insider Monkey)
Feb-05-24 08:00AM	2 Cathie Wood Stocks I Plan on Buying for My Kids' Portfolios (Motley Fool)
Feb-04-24 02:35PM	Got $100? 2 Top Cathie Wood Stocks to Buy and Hold. (Motley Fool)
Feb-02-24 06:00PM	CRISPR Therapeutics AG (CRSP) Rises But Trails Market: What Investors Should Know (Zacks)
Feb-01-24 09:10PM	Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements (InvestorPlace)
Jan-31-24 12:28PM	3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential (InvestorPlace)
Jan-30-24 05:10AM	History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does. (Motley Fool)
05:02AM	Is CRISPR Therapeutics a Buy in the New Bull Market? (Motley Fool)
Jan-28-24 05:10AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week (Motley Fool)
Jan-25-24 06:15PM	CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know (Zacks)
08:32AM	Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January (InvestorPlace)
Jan-24-24 09:45AM	Where Will CRISPR Therapeutics Be in 5 Years? (Motley Fool)
Jan-23-24 09:30AM	1 Setback and 1 Opportunity for CRISPR Therapeutics Stock (Motley Fool)
Jan-22-24 09:12AM	Cathie Woods Latest Stock Picks: 11 Biggest Positions (Insider Monkey) +5.28%
05:05AM	Could CRISPR Therapeutics Stock Help You Become a Millionaire? (Motley Fool)

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kulkarni Samarth	Chief Executive Officer	Apr 15 '24	Option Exercise	19.12	19,582	374,408	227,704	Apr 17 05:45 PM
Kulkarni Samarth	Chief Executive Officer	Apr 15 '24	Sale	59.91	19,582	1,173,232	208,122	Apr 17 05:45 PM
Kulkarni Samarth	Chief Executive Officer	Mar 15 '24	Option Exercise	19.12	20,000	382,400	228,122	Mar 18 05:45 PM
Kulkarni Samarth	Chief Executive Officer	Mar 15 '24	Sale	72.48	20,000	1,449,628	208,122	Mar 18 05:45 PM
Prasad Raju	Chief Financial Officer	Mar 15 '24	Sale	72.69	3,524	256,160	6,476	Mar 18 05:45 PM
Kulkarni Samarth	Chief Executive Officer	Mar 12 '24	Sale	74.44	4,583	341,159	208,122	Mar 12 05:45 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 12 '24	Sale	74.44	1,146	85,308	61,174	Mar 12 05:45 PM
Kulkarni Samarth	Chief Executive Officer	Mar 11 '24	Sale	78.26	9,802	767,105	203,705	Mar 12 05:45 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 11 '24	Sale	78.26	2,801	219,206	60,070	Mar 12 05:45 PM
Kulkarni Samarth	Chief Executive Officer	Feb 20 '24	Sale	79.67	6,370	507,498	194,257	Feb 21 05:45 PM
KASINGER JAMES R.	General Counsel and Secretary	Feb 20 '24	Sale	79.67	1,913	152,409	57,371	Feb 21 05:45 PM
Kulkarni Samarth	Chief Executive Officer	Feb 15 '24	Option Exercise	19.12	20,000	382,400	207,377	Feb 16 05:45 PM
Kulkarni Samarth	Chief Executive Officer	Feb 15 '24	Sale	80.36	20,000	1,607,177	187,377	Feb 16 05:45 PM
Kulkarni Samarth	Chief Executive Officer	Jan 29 '24	Option Exercise	19.12	50,000	956,000	237,377	Jan 31 05:45 PM
Kulkarni Samarth	Chief Executive Officer	Jan 29 '24	Sale	60.51	50,000	3,025,573	187,377	Jan 31 05:45 PM
Kulkarni Samarth	Chief Executive Officer	Jan 16 '24	Option Exercise	19.12	20,000	382,400	207,377	Jan 18 05:45 PM
Kulkarni Samarth	Chief Executive Officer	Jan 16 '24	Sale	62.50	20,000	1,250,058	187,377	Jan 18 05:45 PM
Kulkarni Samarth	Chief Executive Officer	May 30 '23	Option Exercise	19.12	25,000	478,000	412,377	Jun 01 05:44 PM
Kulkarni Samarth	Chief Executive Officer	May 30 '23	Sale	64.88	25,000	1,621,894	387,377	Jun 01 05:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRSP

CRISPR Therapeutics AG

Upgrade your FINVIZ experience